Extensively drug-resistant tuberculosis: Is its definition correct?

European Respiratory Journal

Volumn 32, Issue 5, 2008, Pages 1413-1415

  Caminero, J A ^a  

^a HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMINOSALICYLIC ACID; CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; POLYPEPTIDE ANTIBIOTIC AGENT; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE; THIOAMIDE; VIOMYCIN;

BACTERICIDAL ACTIVITY; DRUG SENSITIVITY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; LETTER; MULTIDRUG RESISTANT TUBERCULOSIS; NOMENCLATURE; PRIORITY JOURNAL;

ANTITUBERCULAR AGENTS; COMMUNICABLE DISEASES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; INFECTIOUS DISEASE MEDICINE; PUBLIC HEALTH; PULMONARY MEDICINE; RIFAMPIN; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 58849118895     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00094708     Document Type: Letter

References (15)

1. Migliori GB, Besozzi G, Girardi E, et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J 2007; 30: 623-626.
2. Migliori GB, Lange C, Centis R, et al. Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur Respir J 2008; 31: 1155-1159.
3. World Health Organization. The global MDR-TB & XDR-TB response plan 2007-2008. Geneva, World Health Organization, 2007.
4. Raviglione MC, Smith IM. XDR tuberculosis - implications for global public health. N Engl J Med 2007; 356: 656-659.
5. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis in a rural area of South Africa. Lancet 2006; 368: 1575-1580.
6. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. Morb Mortal Wkly Rep 2006; 55: 301-305.
7. Jeon CY. Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcome among patients at a tertiary referral hospital. Clin Infect Dis 2008; 46: 42-49.
8. Tousek J, Jancik E, Zelenka M, Jancikova-Máková M. The results of treatment in patients with cultures resistant to streptomycin, isoniazid and PAS, a five-year follow-up. Tubercle 1967; 48: 27-31.
9. Zierski M, Zachara A. Late results in re-treatment of patients with pulmonary tuberculosis. Tubercle 1970; 51: 172-177.
10. Somner AR, Brace AA. Late results of treatment of chronic drug-resistant pulmonary tuberculosis. BMJ 1966; 1: 775-778.
11. Fischer DA, Lester W, Dye WE, Moulding TS. Re-treatment of patients with isoniazid-resistant tuberculosis. Analysis and follow-up of 146 cases. Am Rev Respir Dis 1968; 97: 392-398.
12. Kass I. Chemotherapy regimens used in retreatment ofpulmonary tuberculosis. I. Observations on the efficacy of combinations of kanamycin, ethionamide and either cycloserine or pyrazinamide. Tubercle 1965; 46: 151-165.
13. Pines A. Treatment of pulmonary tuberculosis with cultures resistant to two or more drugs: a series of 44 patients. Tubercle 1965; 46: 131-142.
14. Kass I. Chemotherapy regiments used in retreatment of pulmonary tuberculosis. II. Observations on the efficacy of combinations of ethambutol, capreomycin and companion drugs, including 4-4 diisoamyloxythiosemicarbanilide. Tubercle 1965; 46: 166-177.
15. Caminero JA. Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis 2006; 10: 829-837.